AUPH Aurinia Pharmaceuticals Inc
$16.10▼ -0.06%
Healthcare
Other
After hours
$16.10▲ +0.00%
Sep 11, 7:30 PM ET
Volume 745.4K
Avg Volume (10D) 759.5K
Key Metrics & Fundamentals
Market Cap
$2.14B
P/E Ratio
7.1
Div Yield
–%
52W Range
10.34 - 19.25
% vs 50 MA
1.89%
% vs 200 MA
3.83%
RSI-14
50.9
MACD Histogram
-0.0400
Beta (1Y vs SPY)
0.61
Free Cash Flow
$52.57M
Gross Rev
$83.22M
Gross Profit
$76.67M
EBITDA
$54.57M
COGS
$6.56M
Operating Exp
$30.32M
Operating Income
$46.34M
EBIT
$46.34M
Pretax Income
$48.79M
Net Income
$37.41M
EPS (Diluted)
0.28
Price & Volume History
Loading chart…
Recent News
Immatics and 4 More Stocks See Action From Activist Investors
Barrons.com · Sep 4, 2026 10:59 PM
LB Pharmaceuticals Names Joseph Miller CFO
MT Newswires · Sep 3, 2026 12:38 PM
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
Insider Monkey · Aug 28, 2026 9:14 PM
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback
Simply Wall St. · Aug 20, 2026 7:11 AM
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain
Simply Wall St. · Aug 20, 2026 12:16 AM
AUPH Stock Rallies 6% After-Hours — Here’s Why
Stocktwits · Aug 19, 2026 10:15 PM
Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours
MT Newswires · Aug 19, 2026 8:37 PM
Aurinia Settles Patent Litigation with Teva
Business Wire · Aug 19, 2026 8:05 PM
RBC Adjusts PT on Aurinia Pharmaceuticals to $16 From $15, Keeps Sector Perform Speculative Risk Rating
MT Newswires · Aug 7, 2026 12:13 PM
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Zacks · Aug 6, 2026 1:50 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See AUPH's money flow as a full page
Social Sentiment
No Reddit posts found for AUPH.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.